Miyazaki Masaki, Naoki Katsuhiko, Sato Takashi, Tanaka Kyuto, Tsuzuki Keishi, Yoshida Shuichi, Tomomatsu Katsuyoshi, Tasaka Sadatomo, Soejima Kenzo, Sayama Koichi, Asano Koichiro
Dept. of Internal Medicine, Keio University School of Medicine, Japan.
Gan To Kagaku Ryoho. 2012 Mar;39(3):421-4.
A 65-year-old man was pointed out to have an abnormal lung shadow by chest radiograph in a medical examination in 2007. An extensive examination diagnosed him as a case of advanced lung adenocarcinoma. He was treated by chemotherapy up to the 5th-line(cisplatin+docetaxel→CPT-11+S-1→amrubicin→gemcitabine+vinorelbine→pemetrexed), and the evaluation after the 5th-line treatment revealed disease progression. As he still maintained good performance status, the 6th- line treatment with carboplatin(AUC6, day 1)+paclitaxe(l 200mg/m2, day 1)(Q3W)was administered in March, 2010. The tumor size had been increasing slightly after 2 courses of chemotherapy, although it was within the range of stable disease. Therefore, bevacizumab(15mg/kg, day 1)was added after the 3rd course of treatment, and the tumor began shrinking obviously with cavity formation. Although the positioning of bevacizumab has not been established after 2nd-line treatment for advanced non-small cell lung carcinoma, we experienced a case of good tumor response by adding the bevacizumab in the middle of the 6th-line chemotherapy.
